Rakuten Medical Initiates First-in-Human Phase 1 Trial of PD-L1-Targeted RM-0256 Photoimmunotherapy in Japan
Preclinical studies suggest that RM-0256 photoimmunotherapy may target PD-L1-expressing tumor and immunosuppressive cells and inhibit PD-L1/PD-1 interaction, potentially inducing local and systemic antitumor immune responses SAN DIEGO, Nov. 16, 2026 — Rakuten…

















